Earnings History Data for Editas Medicine, Inc. (EDIT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Editas Medicine, Inc.

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-08-2024	PM		EDIT	Editas Medicine, Inc.	411.19	-0.82	-0.69	-0.56	Editas Medicine GAAP EPS of -$0.82 misses by $0.13, revenue of $0.51M misses by $3.63M [8/7/2024 7:01 AM]	4.12	-0.55 (-11.86%)	4.75	0.07 (1.48%)	4.08 - 11.69	2,722,667	1,440,000	31,780
Editas Medicine Q2 2024 Earnings Preview [8/6/2024 12:06 PM] Editas Medicine GAAP EPS of -$0.82 misses by $0.13, revenue of $0.51M misses by $3.63M [8/7/2024 7:01 AM]
08-05-2024	PM		EDIT	Editas Medicine, Inc.	463.07	-0.76	-0.63	-0.71	Editas Medicine GAAP EPS of -$0.76 misses by $0.18, revenue of $1.14M misses by $6.16M [5/8/2024 7:05 AM]	5.04	-0.64 (-11.36%)	5.04	0.0 (0.00%)	4.91 - 11.91	4,127,577	1,650,000	3,815

28-02-2024	PM		EDIT	Editas Medicine	638.00	-0.23	-0.43	0.00	Editas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32M [2/28/2024 7:01 AM]	11.11	2.25 (25.34%)	10.13	1.27 (14.33%)	6.08 - 11.91	6,642,349	1,750,000	134,268
Editas Medicine Q4 2023 Earnings Preview [2/27/2024 12:23 PM] Editas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32M [2/28/2024 7:01 AM] Editas spikes as Vertex Pharma deal boosts Q4 topline [2/28/2024 8:24 AM]
03-11-2023	PM		EDIT	Editas Medicine, Inc.	545.31	-0.55	-0.64	-0.81	Editas Medicine beats top and bottom line estimates [11/3/2023 7:03 AM]	8.33	1.30 (18.49%)	7.20	0.17 (2.42%)	6.08 - 13.94	3,610,420	1,440,000	8,670
Editas Medicine Q3 2023 Earnings Preview [11/2/2023 11:27 AM] Editas Medicine beats top and bottom line estimates [11/3/2023 7:03 AM] Editas Medicine spikes after Q3 results [11/3/2023 10:23 AM]
02-08-2023	PM		EDIT	Editas Medicine, Inc.	605.78	-0.56	-0.76	-0.78	Editas Medicine GAAP EPS of -$0.56 beats by $0.21, revenue of $2.89M misses by $1.5M [8/2/2023 7:07 AM]	9.14	0.49 (5.66%)	8.46	-0.19 (-2.20%)	6.33 - 19.97	2,522,803	1,360,000	3,555
Editas Medicine Q2 2023 Earnings Preview [8/1/2023 12:56 PM] Editas Medicine GAAP EPS of -$0.56 beats by $0.21, revenue of $2.89M misses by $1.5M [8/2/2023 7:07 AM]
05-05-2023	PM	6:30 AM ET (May 5)	EDIT	Editas Medicine, Inc.	542.98	-0.71	-0.79	-0.74	Editas Medicine GAAP EPS of -$0.71 beats by $0.08 [5/5/2023 7:05 AM]	9.79	1.06 (12.21%)	8.85	0.13 (1.49%)	6.33 - 19.97	3,982,749	1,660,000	9,077
Editas Medicine Q1 2023 Earnings Preview [5/4/2023 12:39 PM] Editas Medicine GAAP EPS of -$0.71 beats by $0.08 [5/5/2023 7:05 AM]
22-02-2023	PM	6:30 AM ET (Feb 22)	EDIT	Editas Medicine, Inc.	684.88	-0.88	-0.84	-0.61	Editas Medicine GAAP EPS of -$0.88 misses by $0.08, revenue of $6.54M beats by $2.78M [2/22/2023 6:21 AM]	9.72	0.54 (5.94%)	9.45	0.27 (2.94%)	7.70 - 21.59	1,486,352	1,510,000	1,561
Editas Medicine GAAP EPS of -$0.88 misses by $0.08, revenue of $6.54M beats by $2.78M [2/22/2023 6:21 AM] Editas Medicine Q4 2022 Earnings Preview [2/21/2023 11:09 AM] Editas rises on Q4 revenue beat, gene-editing therapy data for sickle cell disease by mid-year [2/22/2023 12:28 PM]
02-11-2022	PM	6:30 AM ET (Nov 2)	EDIT	Editas Medicine, Inc.	862.65	-0.81	-0.87	-0.57	Editas Medicine GAAP EPS of -$0.81 beats by $0.07 [11/2/2022 6:32 AM]	12.92	0.17 (1.33%)	12.95	0.20 (1.57%)	9.59 - 42.11	1,939,552	0	13,080
Editas Medicine Q3 2022 Earnings Preview [11/1/2022 1:15 PM] Editas Medicine GAAP EPS of -$0.81 beats by $0.07 [11/2/2022 6:32 AM] Editas Medicine rises 7% on Q3 earnings beat [11/2/2022 11:43 AM]
03-08-2022	PM	6:45 AM ET (Aug 3)	EDIT	Editas Medicine, Inc.	1,090	-0.78	-0.84	-0.81	Editas Medicine GAAP EPS of -$0.78 beats by $0.06, revenue of $6.36M beats by $2.07M [8/3/2022 6:30 AM]	18.66	2.18 (13.23%)	17.34	0.86 (5.22%)	9.59 - 73.03	2,576,538	1,560,000	8,859
Editas Medicine Q2 2022 Earnings Preview [8/2/2022 11:58 AM] Editas Medicine GAAP EPS of -$0.78 beats by $0.06, revenue of $6.36M beats by $2.07M [8/3/2022 6:30 AM] Editas Medicine up 13% following Q2 2022 top and bottom line beats as net loss narrows [8/3/2022 10:43 AM] Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics [8/3/2022 2:58 PM] Editas Medicine Announces Second Quarter 2022 Results and Business Updates [Aug-03-22 06:29AM]
04-05-2022	PM	6:30 AM ET (May 4)	EDIT	Editas Medicine	907.00	-0.74	-0.81	0.00	Editas Medicine GAAP EPS of -$0.74 beats by $0.07, revenue of $6.77M beats by $2.92M [5/4/2022 6:46 AM]	15.82	1.64 (11.57%)	14.10	-0.08 (-0.56%)	12.90 - 73.03	1,260,146	1,570,000	3,541
Editas Medicine Q1 2022 Earnings Preview [5/3/2022 2:00 PM] Editas Medicine GAAP EPS of -$0.74 beats by $0.07, revenue of $6.77M beats by $2.92M [5/4/2022 6:46 AM] Editas Medicine Announces First Quarter 2022 Results and Business Updates [May-04-22 06:45AM] Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 07:55AM] Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference [May-04-22 01:30PM] Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates [May-04-22 11:54AM]
24-02-2022	PM	7:00 AM ET (Feb 24)	EDIT	Editas Medicine, Inc.	1,030	-0.61	-0.78	1.00	Editas Medicine GAAP EPS of -$0.61 beats by $0.13, revenue of $12.47M [2/24/2022 6:35 AM]	15.85	1.44 (9.99%)	0.0	0.0 (0.00%)	13.25 - 73.03	1,829,827	1,816,326	0
Editas Medicine Q4 2021 Earnings Preview [2/23/2022 12:31 PM] Editas Medicine GAAP EPS of -$0.61 beats by $0.13, revenue of $12.47M [2/24/2022 6:35 AM] Editas Medicine net loss narrows as its beats on bottom line [2/24/2022 10:36 AM] Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More [Feb-23-22 11:44AM] 10 Genomics Stocks in Cathie Woods Portfolio That Are Underperforming [Feb-23-22 09:54AM] Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates [Feb-24-22 06:30AM] Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates [Feb-24-22 07:45AM]
08-11-2021	PM	7:00 AM ET (Nov 8)	EDIT	Editas Medicine, Inc.	2,580	-0.57	-0.86	0.12	Editas Medicine EPS beats by $0.27, beats on revenue [11/8/2021 7:03 AM]	40.62	3.12 (8.32%)	38.00	0.50 (1.33%)	27.33 - 99.95	2,257,554	870,000	30,852
Editas Medicine EPS beats by $0.27, beats on revenue [11/8/2021 7:03 AM] Editas narrows net loss further; to begin dosing in sickle cell disease trial in H1 2022 [11/8/2021 7:40 AM] Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More [Nov-05-21 10:09AM] Editas Medicine Announces Third Quarter 2021 Results and Business Updates [Nov-08-21 07:00AM] Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates [Nov-08-21 08:25AM] Why Editas Medicine Stock Is Jumping Today [Nov-08-21 12:52PM] Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript [Nov-08-21 04:00PM]
04-08-2021	PM	7:00 AM ET (Aug 4)	EDIT	Editas Medicine, Inc.	2,820	-0.81	-0.85	-0.43	Editas Medicine EPS beats by $0.03, misses on revenue [8/4/2021 7:06 AM]	46.05	3.94 (9.36%)	46.05	0.0 (0.00%)	27.01 - 99.95	1,948,646	870,000	52,699
Editas Medicine Q2 2021 Earnings Preview [8/3/2021 12:49 PM] Editas Medicine EPS beats by $0.03, misses on revenue [8/4/2021 7:06 AM] Editas Medicine Q2 net loss more than doubles; reiterates upcoming milestones [8/4/2021 7:54 AM] Editas Medicine Announces Second Quarter 2021 Results and Business Updates [Aug-04-21 07:00AM] Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates [Aug-04-21 08:15AM] Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript [Aug-04-21 05:30PM]
05-05-2021	PM	7:00 AM ET (May 5)	EDIT	Editas Medicine, Inc.	2,500	-0.86	-0.76	-0.69	Editas Medicine EPS misses by $0.11, beats on revenue [5/5/2021 7:02 AM]	34.72	0.06 (0.17%)	34.72	0.0 (0.00%)	23.51 - 99.95	1,356,469	1,020,000	17,456
Editas Medicine Q1 2021 Earnings Preview [5/4/2021 2:03 PM] Intellia and Sangamo preferred as RBC extends gene editing coverage [5/4/2021 1:57 PM] Editas Medicine EPS misses by $0.11, beats on revenue [5/5/2021 7:02 AM] Editas strengthens Q1 liquidity despite rising net loss; names new chief scientific officer [5/5/2021 7:33 AM] Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting [May-04-21 09:00AM] Editas Medicine, Inc. to Host Earnings Call [May-05-21 06:15AM] Editas Medicine Announces First Quarter 2021 Results and Update [May-05-21 07:00AM] Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer [May-05-21 06:59AM] Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates [May-05-21 08:20AM] Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat [May-05-21 11:05AM] What Really Mattered With Editas Medicine's Q1 Update [May-05-21 02:46PM] Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript [May-05-21 04:30PM]
25-02-2021	PM	7:00 AM ET (Feb 25)	EDIT	Editas Medicine, Inc.	3,090	-1.00	-0.81	-0.74	Editas Medicine EPS misses by $0.12, beats on revenue [2/25/2021 7:17 AM]	44.71	-4.99 (-10.04%)	48.41	-1.29 (-2.60%)	14.01 - 99.95	3,359,285	2,737,524	28,059
Editas Medicine EPS misses by $0.12, beats on revenue [2/25/2021 7:17 AM] Editas Medicine Q4 2020 Earnings Preview [2/24/2021 12:34 PM] Editas falls again as quarterly loss widens amid revenue slip [2/25/2021 9:24 AM] Editas Medicine downgraded to underweight at JP Morgan on lack of catalysts [2/25/2021 4:16 PM] Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript [Feb-25-21 01:00PM] Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update [Feb-25-21 07:00AM] Editas Medicine, Inc. to Host Earnings Call [Feb-25-21 05:45AM]
05-11-2020	AH	4:05 PM ET (Nov 5)	EDIT	Editas Medicine, Inc.	1,760	0.12	-0.64	-0.66	Editas Medicine EPS beats by $0.78, beats on revenue [11/5/2020 4:14 PM]	30.52	-1.03 (-3.26%)	32.00	0.45 (1.43%)	14.01 - 39.96	574,457	826,793	1,577

06-08-2020	AH	4:00 PM ET (Aug 6)	EDIT	Editas Medicine, Inc.	1,960	-0.43	-0.80	-0.69	Editas Medicine EPS beats by $0.40, beats on revenue [8/6/2020 4:07 PM]	34.31	-2.53 (-6.87%)	35.00	-1.84 (-4.99%)	14.01 - 39.96	1,300,017	1,061,264	20,192